Design and optimization of liquisolid compact based vaginal sustained release tablet of antifungal agent for vaginal candidiasis

Kanojiya, Pranita S.; Ghodake, Pradip N.; Wadetwar, Rita N.

doi:10.1080/01932691.2022.2158854

Cited by 6 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For any drug to elicit the desired action, the drug must get solubilized first. 17 Thus, the formation of inclusion complex based tablet helped to overcome the dissolution issue. Generally, the hydrophilic matrix polymers such as HPMC when used in the formulation give the mechanism through the disentanglement and swelling of the polymer.…”

Section: Discussionmentioning

confidence: 99%

“…The similar results were obtained in the study with NLC gel of Voriconazole and Lawsone liquisolid tablet. 1,17 The currently available marketed vaginal medicated products (such as Monistat, Candid V etc.) 28 when applied frequently cause sensation of burning, redness and tingling feeling to the female patients during the course of the treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Where m = weight required for detachment in grams, g = acceleration due to gravity (980 cm/s 2 ) and A = area of the vaginal mucosa exposed. 13,17 Swelling study…”

Section: Ex Vivo Mucoadhesion Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Formulation and Evaluation of Antifungal Drug Containing Mucoadhesive Tablet for Vaginal Candidiasis

Kanojiya,

Wadetwar,

Godbole

2023

Ind. J. Pharm. Edu. Res.

View full text Add to dashboard Cite

Objectives: Female population frequently seeks medical consultation for the vaginal candidiasis. Voriconazole (VOR) is a BCS class II antifungal drug with low aqueous solubility and hence inclusion complex was formulated using Hydroxypropyl-β-cyclodextrin (HPβCD). The complex was incorporated into mucoadhesive vaginal tablet using Chitosan and Hydroxypropyl Methyl Cellulose (HPMC K100). Materials and Methods: A 3 2 full factorial design was employed for sustained release tablet using Design expert® software. Results: Scanning Electron Microscopy (SEM) results indicated the complex formation between the drug and HPβCD. The batches showed 39.68±1.2 to 72.31±1.4% of drug release for 4 hr while for 8 hr it was from 77.23±1.5 to 99.82±1.1%. Therefore, the sustained release of drug was achieved for 8 hr. The tablet batches had swelling % from 228.51±12 to 323.11±8% and mucoadhesive strength from 1131.02±49 to 2302.12±55 dyne/cm 2 . In the in vitro antifungal activity study, a higher zone of inhibition was observed for the inclusion complex-based tablet (34±0.3 mm) as compared to plain drug tablet (25±0.4 mm). Conclusion: Therefore, the inclusion complex-based vaginal tablet could be formulated successfully by employing 3 2 full factorial design for increased residence of drug at the vaginal site of infection and for improved therapeutic efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%